Compile Data Set for Download or QSAR
Report error Found 1188 Enz. Inhib. hit(s) with Target = 'Histone acetyltransferase KAT7'
LigandPNGBDBM730964(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731036(US20250122183, Example 249)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730882(US20250122183, Example 095)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731005(US20250122183, Example 218)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731043(US20250122183, Example 256)
Affinity DataKi:  0.800nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730972(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.900nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731037(US20250122183, Example 250)
Affinity DataKi:  0.900nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730962(N-{6[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-meth...)
Affinity DataKi:  1nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730859(US20250122183, Example 072)
Affinity DataKi:  1.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731041(US20250122183, Example 254)
Affinity DataKi:  1.20nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730909(US20250122183, Example 122)
Affinity DataKi:  1.20nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731037(US20250122183, Example 250)
Affinity DataKi:  1.30nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731031(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  1.30nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730973(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  1.5nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730965(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  1.5nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730957(US20250122183, Example 170)
Affinity DataKi:  1.60nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731003(US20250122183, Example 216)
Affinity DataKi:  1.60nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730971(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  1.60nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731036(US20250122183, Example 249)
Affinity DataKi:  1.70nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM731000(US20250122183, Example 213)
Affinity DataKi:  1.70nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731034(US20250122183, Example 247)
Affinity DataKi:  1.70nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730933((stereospecific Procedure): N-{6-[(3-cyclopropyl-1...)
Affinity DataKi:  1.70nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730972(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  1.80nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731006(US20250122183, Example 219)
Affinity DataKi:  1.90nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730834(US20250122183, Example 047)
Affinity DataKi:  1.90nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731004(US20250122183, Example 217)
Affinity DataKi:  1.90nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730901(US20250122183, Example 114)
Affinity DataKi:  2.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731038(US20250122183, Example 251)
Affinity DataKi:  2.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730908(US20250122183, Example 121)
Affinity DataKi:  2.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730970(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  2.10nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730858(US20250122183, Example 071)
Affinity DataKi:  2.20nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730834(US20250122183, Example 047)
Affinity DataKi:  2.20nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731052(US20250122183, Example 265)
Affinity DataKi:  2.30nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731017(US20250122183, Example 230)
Affinity DataKi:  2.30nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM731013(US20250122183, Example 226)
Affinity DataKi:  2.40nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730933((stereospecific Procedure): N-{6-[(3-cyclopropyl-1...)
Affinity DataKi:  2.40nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731035(US20250122183, Example 248)
Affinity DataKi:  2.60nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731034(US20250122183, Example 247)
Affinity DataKi:  2.70nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730963(N-{6[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-meth...)
Affinity DataKi:  2.70nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730955(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl}amino]-5-met...)
Affinity DataKi:  2.70nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730975(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  2.90nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF2+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731013(US20250122183, Example 226)
Affinity DataKi:  3nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730990(US20250122183, Example 203)
Affinity DataKi:  3nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730909(US20250122183, Example 122)
Affinity DataKi:  3nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730933((stereospecific Procedure): N-{6-[(3-cyclopropyl-1...)
Affinity DataKi:  3.20nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730956(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  3.20nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730988(US20250122183, Example 201)
Affinity DataKi:  3.40nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM731023(US20250122183, Example 236)
Affinity DataKi:  3.5nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT7/Peregrin(Human)
Pfizer

US Patent
LigandPNGBDBM730782(US20250122183, Example 002)
Affinity DataKi:  3.5nMAssay Description:1. Final reaction conditions are 2 nM KAT7+BRPF1+EAF6+ING54-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

LigandPNGBDBM730973(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  3.60nMAssay Description:1. Final reaction conditions are 4 nM KAT7+JADE1+EAF6+ING5 4-protein complex, 1 μM AcCoA, 2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

Displayed 1 to 50 (of 1188 total ) | Next | Last >>
Jump to: